Ambrx Biopharma — Merger or Acquisition (February 2024)
18 slides from Ambrx Biopharma's merger presentation, Feb 15, 2024
Slide 1: Slide 1
Slide 2: We’re pleased to join you today
We’re pleased to join you today Danka Connor Meret MO ‘hart Eesyed MO, Meise PRO Senamin vine, A esooeand bees Serene) ota rs) ere
Slide 3: Slide 3
Slide 4: We use our breadth and scale to change and save lives
We use our breadth and scale to change and save lives #2 ‘Ranked pharma company for REO Investment in 2032 ey $14.6B Invested in research and development (REO) ‘orors ourbusinesier >460M Pasents globally treated with ‘ur produets in 2088
Slide 5: Johnson&Johnson Innovative Medicine and MedTech
Johnson&Johnson Innovative Medicine Johnson&Johnson MedTech
Slide 6: Slide 6
Slide 7: Delivering
Delivering 23in the ast decade and expecting to deliver even ‘more innovations that improve and save lives Gaining transformational Ey tearslotne the promise of dats scene, incudiog digital health, Al, and realworld evidence by listening to patients through the Patient Voice in Clinical Trial Progra
Slide 8: We're focused in areas where patient need is high
We're focused in areas where patient need is high, market opportunity is significant, and our expertise is deep Neuroscience Select isease areas + Schizophrenia + Thrombosis + Depression + Retinal Osease + Alaheime’s Disease “+ Pulmonary Hypertension + Myasthenia Gravis + cape:
Slide 9: Our future growth will be fueled by 20+ novel therapies
Our future growth will be fueled by 20+ novel therapies and 50+ product expansions*
Slide 10: Our mission
(Our mission ‘Our ambition Datver curative, synergic weatment Our progress 2M patents treated with 183 Oncology medicine worldwide
Slide 11: Strong Oncology Growth Trajectory
Strong Oncology Growth Trajectory ‘Advancing a strategy to deliver a deep, diverse portfolio of first and best in class assets omy AR 21% oe tye? sm
Slide 12: Disease Areas of Focus
Disease Areas of Focus Global rate of new cancer diagnoses is expected to rise by 69% by 2030 Deaths from cancer are expected to rise by 72% by 2030 * Prostate Hematologic tung Cy Bladder iam / 2375k = ->1.3M / >712K = >2.2M />1.8M — > 570K _/ >213K erences eretoeetare instr erm ety oe parsons teens
Slide 13: J&J in Oncology — leadership, innovation, growth
J&J in Oncology — leadership, innovation, growth Continuing a legacy of delivering new drugs and advancing a pipeline with transformational potential recedes rea rg Cees ed vere anezeem omencaner lecuedbasie avery rs)
Slide 14: What’s next?
What’s next? IRS emt tema
Slide 15: Ambrx and J&J: Key upcoming engagements
Ambrx and J&J: Key upcoming engagements Companies will emia separate unt al regulatory approvals are obtained —— OS an tana Dane Dentegnen ails peters Oo) ano Medicine, the ‘oncslogyoipeline sd Bortolta and new steps. @ tie ort mete © eommonicaion Siming of sis. Inegrasoniurey Meet leam more about I
Slide 16: os
os
Slide 17: IRS emt tema
IRS emt tema
Slide 18: Forward-Looking Statements
Forward-Looking Statements These communications contain “forward-looking statements” regarding the acquisition of Ambrx Biopharma, Inc. (“Ambrx”). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlyi
Ambrx Biopharma — Merger or Acquisition (February 2024) on 6ix